New drug tested for Hard-to-Treat liver disease
NCT ID NCT03217422
Summary
This study tested a new drug called VAY736 for adults with autoimmune hepatitis, a condition where the body's immune system attacks the liver. It was for patients whose disease was not fully controlled by standard medications or who couldn't tolerate them. Researchers compared different doses of VAY736 against a placebo to see if it was safe and could help normalize liver function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEPATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Inland Empire Liver Foundation
Rialto, California, 92377, United States
-
Novartis Investigative Site
CABA, Buenos Aires, C1056ABI, Argentina
-
Novartis Investigative Site
CABA, C1181ACH, Argentina
-
Novartis Investigative Site
Ghent, 9000, Belgium
-
Novartis Investigative Site
Edmonton, Alberta, T6G 2B7, Canada
-
Novartis Investigative Site
Toronto, Ontario, M5G 2C4, Canada
-
Novartis Investigative Site
Montreal, Quebec, H2X 1R9, Canada
-
Novartis Investigative Site
Prague, 12000, Czechia
-
Novartis Investigative Site
Würzburg, Bavaria, 97080, Germany
-
Novartis Investigative Site
Aachen, 52074, Germany
-
Novartis Investigative Site
Hamburg, 20246, Germany
-
Novartis Investigative Site
Hanover, 30625, Germany
-
Novartis Investigative Site
Mainz, 55131, Germany
-
Novartis Investigative Site
Sapporo, Hokkaido, 0068555, Japan
-
Novartis Investigative Site
Takamatsu, Kagawa-ken, 760 8557, Japan
-
Novartis Investigative Site
Itabashi Ku, Tokyo, 173 8606, Japan
-
Novartis Investigative Site
Barcelona, 08036, Spain
-
Novartis Investigative Site
Madrid, 28009, Spain
-
Novartis Investigative Site
Madrid, 28046, Spain
-
Novartis Investigative Site
Bern, 3010, Switzerland
-
Novartis Investigative Site
Birmingham, West Midlands, B15 2TH, United Kingdom
-
Novartis Investigative Site
London, SE5 9RS, United Kingdom
-
Novartis Investigative Site
Newcastle upon Tyne, NE1 4LP, United Kingdom
-
Novartis Investigative Site
Nottingham, NG7 2UH, United Kingdom
-
Novartis Investigative Site
Oxford, OX3 9DU, United Kingdom
-
Southern California Research Center
Coronado, California, 92118, United States
-
St. Lukes Advanced Liver Therapies
Houston, Texas, 77030, United States
-
University of California Davis Medical Center
Sacramento, California, 95817, United States
Conditions
Explore the condition pages connected to this study.